Drugs & Targets FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC June 20, 2025Vol.51 No.24
Drugs & Targets FDA approves tablet formulation of Brukinsa for five approved indications June 13, 2025Vol.51 No.23
Drugs & Targets FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC June 13, 2025Vol.51 No.23
Drugs & Targets SU2C, SandboxAQ collaborate to accelerate treatment innovation June 13, 2025Vol.51 No.23
Drugs & Targets FDA approves Nubeqa for metastatic castration-sensitive prostate cancer June 06, 2025Vol.51 No.22
Drugs & Targets Clairity becomes the first FDA-authorized AI platform for breast cancer prediction June 06, 2025Vol.51 No.22
Drugs & Targets EC approves Adcetris for newly diagnosed Hodgkin lymphoma in combination with ECADD June 06, 2025Vol.51 No.22
Drugs & Targets China’s NMPA approves zanidatamab in China for previously treated, unresectable or metastatic HER2+ biliary tract cancer June 06, 2025Vol.51 No.22
Drugs & Targets Meitheal Pharmaceuticals launches generic paclitaxel formulation in the U.S. June 06, 2025Vol.51 No.22
